Eli Lilly and Company (LLY) Stock Analysis
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.
About Eli Lilly and Company
Eli Lilly is a global pharmaceutical company focused on endocrinology, oncology, immunology, and neuroscience. The company has become the most valuable pharma company in the world thanks to its GLP-1 receptor agonist drugs — Mounjaro (for type 2 diabetes) and Zepbound (for obesity). These drugs represent the largest new drug class in pharmaceutical history, addressing a market of hundreds of millions of patients globally.
How Eli Makes Money
Lilly discovers, develops, manufactures, and sells pharmaceutical products globally. Revenue comes from drug sales across therapeutic areas, with GLP-1 drugs (Mounjaro/Zepbound) representing the dominant growth driver. The company invests ~25% of revenue in R&D and operates its own manufacturing facilities. Lilly sells through pharmacies, hospitals, and specialty channels, with reimbursement from insurance and government payers.
Eli Revenue & Profitability Breakdown
This chart shows how Eli's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
A snapshot of the company's valuation, growth, profitability, and financial health. Key things to look at: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business — companies with strong FCF can buy back shares, pay dividends, or invest; Debt/Equity shows how leveraged the company is (high debt can be risky); Return on Equity tells you how efficiently the company generates profit from shareholders' money.
Wall Street Analyst Consensus
Professional analysts at investment banks set 12-month price targets after researching the company's earnings, competitive position, and industry trends. Strong Buy / Buy means the majority expect meaningful upside. Hold means analysts see fair value near the current price — not a sell signal, but limited near-term upside expected. The mean target is the average of all analyst price targets; the range shows where the most optimistic and most cautious analysts stand.
Intrinsic Value Estimates for LLY
Intrinsic value is what a stock is truly worth based on the company's fundamentals — independent of what the market currently prices it at. We use multiple models because no single formula is perfect: each captures different aspects of a business. If multiple models agree the stock is undervalued, that convergence is a stronger signal. A stock trading well below its intrinsic value may be a bargain; one far above may carry more risk.
⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.
LLY Investment Case: Bull vs Bear
Every investment has two sides. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks that could cause the investment to underperform. Good investors read both sides carefully before deciding. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- GLP-1 obesity market could be $100B+ annually by 2030 — Lilly's Zepbound and oral GLP-1 (orforglipron) position it to capture a dominant share of this generational opportunity.
- Manufacturing scale-up investments ($20B+) will resolve current supply constraints and unlock massive revenue acceleration through 2026-2028.
- Pipeline beyond GLP-1 includes potential blockbusters in Alzheimer's (donanemab), immunology, and oncology — the company is not a one-trick pony.
- Obesity drugs show cardiovascular, kidney, liver, and sleep apnea benefits beyond weight loss, expanding the addressable patient population dramatically.
Bear Case (Key Risks)
- Valuation is extreme (50x+ forward P/E) and already prices in blockbuster GLP-1 scenarios — any clinical setback or competitive pressure could cause a sharp correction.
- Novo Nordisk (Ozempic/Wegovy) is a formidable competitor with first-mover advantage and its own next-generation obesity candidates.
- GLP-1 drug discontinuation rates are high (~70% at one year) — long-term compliance and real-world adherence remain question marks.
- Payer pushback on pricing ($1,000+/month) and potential Medicare negotiation under the Inflation Reduction Act could compress margins.
What to Watch: LLY Key Metrics
LLY Stock — Frequently Asked Questions
Compare LLY with Peers
Unlock the Full LLY Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 21-day free trial — no credit card required.